Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.37%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.48 per share when it actually produced a loss of $0.38, delivering a surprise of 20.83%.Over the last four quarters, the company ha ...

财务业绩 - 公司在2024年6月30日季度的合作收入为15,083,000美元，较2023年同期下降41,131,000美元[54,57] - 公司在2024年6月30日季度的研发费用为46,314,000美元，较2023年同期基本持平[58,59] - 公司在2024年6月30日季度的一般及行政费用为14,375,000美元，较2023年同期增加749,000美元[60] - 公司在2024年6月30日季度的其他收益净额为7,003,000美元，较2023年同期增加646,000美元[61] - 公司在2024年6月30日季度的税前净亏损为38,603,000美元，较2023年同期扩大41,371,000美元[63,64] - 公司在2024年6月30日季度的所得税费用为73,000美元，较2023年同期下降1,320,000美元[62,64] - 公司在2024年6月30日季度的净亏损为38,676,000美元，较2023年同期扩大40,051,000美元[64] - 合作收入同比下降41.1百万美元，主要由于AL101项目收入减少35.7百万美元[65] - 研发费用基本持平，增加0.1百万美元，主要由于公司优先发展后期项目[66] - 一般及行政费用略有增加[68] - 其他收益净额增加0.6百万美元，主要由于投资收益增加[69] - 所得税费用同比下降2.2百万美元，主要由于2023年全额确认GSK收入[70] - 合作收入同比下降41.8百万美元，主要由于AL101和AL002项目收入减少[71,72] - 研发费用同比下降6.6百万美元，主要由于公司优先发展后期项目和人工成本下降[74] - 其他收益净额增加3.1百万美元，主要由于投资收益增加[77] 现金流与财务状况 - 预计现有现金及等价物可支持公司运营至2026年[80] - 公司已采取裁员等措施以更好地配合当前战略重点并维持预期的运营资金[80] 收入确认政策 - 公司采用五步法确认收入确认的适当金额，包括识别合同、识别履约义务、确定交易价格、分配交易价格至履约义务、以及在履约义务完成时确认收入[88] - 公司根据实际发生的成本占预计总成本的比例来确认在研发期间的合作收入[88] 财务风险 - 公司持有503.3百万美元的现金、现金等价物和有价证券，主要包括货币市场基金、美国国债、公司债券、存单和商业票据[89] - 公司面临利率风险，但利率波动对利息收入的影响较小，100个基点的利率变动会导致公允价值变动约250万美元[89] - 公司存在外汇交易风险，但目前外汇交易损益并不重大，汇率变动10%不会对财务状况产生重大影响[90]

财务状况 - 公司现金、现金等价物和投资总额为5.033亿美元，可为公司运营提供资金支持至2026年[25] - 公司三个月和六个月的合作收入分别为1.51亿美元和3.10亿美元[36] - 公司三个月和六个月的研发费用分别为4.63亿美元和9.15亿美元[36] - 公司三个月和六个月的总运营费用分别为6.07亿美元和12.03亿美元[36] - 公司三个月和六个月的营业亏损分别为4.56亿美元和8.93亿美元[36] - 公司三个月和六个月的其他收益净额分别为7,003万美元和1.46亿美元[36] - 公司三个月和六个月的税前亏损分别为3.86亿美元和7.47亿美元[36] - 公司三个月和六个月的净亏损分别为3.87亿美元和7.48亿美元[36] - 公司三个月和六个月的每股基本和稀释亏损分别为0.40美元和0.78美元[36] - 公司三个月和六个月的加权平均股数分别为9,667.49万股和9,524.25万股[36] - 公司预计2024年全年合作收入将在6000万美元至7000万美元之间[26] - 公司预计2024年全年研发费用将在2.1亿美元至2.2亿美元之间[26] - 公司预计2024年全年一般及行政费用将在6000万美元至7000万美元之间[26] 临床试验进展 - 公司正在进行的INFRONT-3 III期临床试验旨在评估latozinemab在FTD-GRN患者中延缓疾病进展的安全性和有效性[11] - INVOKE-2 II期临床试验正在全面入组,预计于2024年第四季度公布数据。该试验旨在评估AL002在早期阿尔茨海默病患者中延缓疾病进展的疗效和安全性[16] - 公司正在进行PROGRESS-AD II期临床试验,评估AL101/GSK4527226在早期阿尔茨海默病患者中的疗效[13] 监管进展 - 公司与FDA就latozinemab在FTD-GRN适应症的潜在生物制品许可申请达成共识,FDA将考虑PGRN浓度作为临床疗效的佐证性证据[10] 技术平台 - 公司正在积极推进其专有的血脑屏障技术平台Alector Brain Carrier (ABC),应用于下一代产品候选药物和研发管线[19] 联系方式 - 公司提供了媒体联系人、投资者联系人等联系方式[37][38][39]

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call. The event will be webcast live under the investor relations ...

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD-- SOUTH SAN FRANCISCO, Calif., July 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno ...

SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024. Poster presentations will be available for on-demand viewing beginning on July 28 at 8:00 a.m. ET. AL002 ...

SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5th Annual Neuro Perspectives Conference, being held virtually on Thursday, June 27, 2024. A webcast of the presentation will be available on the "Events & Presentations" page at 7:00 a.m. ET within the Investors section of the Alector website at http: ...

SOUTH SAN FRANSISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host a virtual event to discuss Alector Brain Carrier, a proprietary, versatile blood-brain barrier (BBB) technology platform that is being applied selectively to the Company’s next-generation product candidates and research pipeline. The event will include a presentation from Alector’s management team as well as a le ...

SOUTH SAN FRANSISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host a virtual event to discuss Alector Brain Carrier, a proprietary, versatile blood-brain barrier (BBB) technology platform that is being applied selectively to the Company’s next-generation product candidates and research pipeline. The event will include a presentation from Alector’s management team as well as a le ...

Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 20.83%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.80 per share when it actually produced a loss of $0.49, delivering a surprise of 38.75%. Over the last four quarters, the company has ...